BioNTech Is Riding A Wave Of COVID-19 Vaccine Demand, But How Long Will It Last?

Company Will Earn Nearly $20bn In 2021

Booster shots could maintain Comirnaty sales in 2022, but a sharp decline is expected in follow years – and so BioNTech needs a long-term growth plan.

Stafford / United Kingdom - November 9 2020: Pfizer BioNTech Covid-19 vaccine concept. Syringe balanced on a fingertip and blurred company logos on the background. Selective focus.
Pfizer and BioNTech now expect to deliver 2.5 billion doses of Comirnaty this year, putting them far ahead of mRNA vaccine rivals Moderna. • Source: Alamy

BioNTech has raised its full-year revenue forecast from its record-breaking COVID-19 vaccine Comirnarty, and now expects to earn €16bn-€17bn ($19.7bn) in 2021.

That is a potential 7% uplift on its BioNTech’s previous forecast of €15.9bn, and in line with the increase its...

More from Business

More from Scrip

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By 

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.